 |
DUBAI, UAE, March 28, 2025 /PRNewswire/ -- The Crypto Content Creator Campus (CCCC) is set to launch a special pilot edition in Bali from April 10 to 13, 2025. Exclusively sponsored by Bybit, the event marks CCCC's official debut in Asia Pacific and will center on the theme: Build Crypto Ark, Bit by Bit.
Hosted in one of Asia's most iconic destinations, CCCC Bali 2025 will bring together around 150 top crypto content creators in Asia Pacific. Alongside them, five prominent speakers will deliver insights into creator growth, audience conversion, and sustainable monetization in the Web3 space. This exclusive, two-day experience will unite some of the biggest names in crypto, content creation, and blockchain for a high-energy, invite-only gathering packed with expert insights, networking, and entertainment.
High-profile crypto influencers and key opinion leaders are expected to attend, including RTA, Head of Trading at RTA Business School; Gong Youchai, co-founder of ANGELAB Quantitative and Blackwater Holding; and MoMo, a leading on-chain arbitrage trader. Other well-known figures with massive online followings — such as Phyrex, BITWU, and Little Penguin — will also share their expertise and engage with the community.
"Following the successful CCCC Dubai 2024, we're thrilled to extend our vision to the vibrant Asia-Pacific crypto community - a place bursting with energy, ambition, and an insatiable appetite for crypto knowledge," said Phoebe Peng, Managing Director of CCCC. "This upcoming event will foster collaboration and equip content creators with creativity to monetize their passion."
Bali was chosen as the launchpad for CCCC's APAC debut not only for its vibrant crypto community, but also for its unique blend of natural beauty and cultural richness — a perfect backdrop to inspire creativity, collaboration, and meaningful storytelling. CCCC aims to empower Asia-Pacific creators in a setting that fuels both imagination and impact.
About Crypto Content Creator Campus (CCCC)
CCCC is a team of industry experts and visionaries committed to shaping the future of content creation within the Web3 and crypto sphere. Driven by a shared passion for creating a high-value community, we've curated a campus that promises an experience unlike any other.
For more details about CCCC, please visit: https://www.cccc.buzz/
For inquiries, please contact: hello@cccc.buzz
Instagram | X
DUBAI, UAE, March 28, 2025 /PRNewswire/ -- The Crypto Content Creator Campus (CCCC) is set to launch a special pilot edition in Bali from April 10 to 13, 2025. Exclusively sponsored by Bybit, the event marks CCCC's official debut in Asia Pacific and will center on the theme: Build Crypto Ark, Bit by Bit.
Hosted in one of Asia's most iconic destinations, CCCC Bali 2025 will bring together around 150 top crypto content creators in Asia Pacific. Alongside them, five prominent speakers will deliver insights into creator growth, audience conversion, and sustainable monetization in the Web3 space. This exclusive, two-day experience will unite some of the biggest names in crypto, content creation, and blockchain for a high-energy, invite-only gathering packed with expert insights, networking, and entertainment.
High-profile crypto influencers and key opinion leaders are expected to attend, including RTA, Head of Trading at RTA Business School; Gong Youchai, co-founder of ANGELAB Quantitative and Blackwater Holding; and MoMo, a leading on-chain arbitrage trader. Other well-known figures with massive online followings — such as Phyrex, BITWU, and Little Penguin — will also share their expertise and engage with the community.
"Following the successful CCCC Dubai 2024, we're thrilled to extend our vision to the vibrant Asia-Pacific crypto community - a place bursting with energy, ambition, and an insatiable appetite for crypto knowledge," said Phoebe Peng, Managing Director of CCCC. "This upcoming event will foster collaboration and equip content creators with creativity to monetize their passion."
Bali was chosen as the launchpad for CCCC's APAC debut not only for its vibrant crypto community, but also for its unique blend of natural beauty and cultural richness — a perfect backdrop to inspire creativity, collaboration, and meaningful storytelling. CCCC aims to empower Asia-Pacific creators in a setting that fuels both imagination and impact.
About Crypto Content Creator Campus (CCCC)
CCCC is a team of industry experts and visionaries committed to shaping the future of content creation within the Web3 and crypto sphere. Driven by a shared passion for creating a high-value community, we've curated a campus that promises an experience unlike any other.
For more details about CCCC, please visit: https://www.cccc.buzz/
For inquiries, please contact: hello@cccc.buzz
Instagram | X
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
From Dubai to Bali: Crypto Content Creator Campus Continues to Empower the Crypto Content Ecosystem
SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of positive topline results from its Phase II randomized, double-blind, placebo-controlled trial of CG2001 at the 14th World Congress for Hair Research (WCHR) in Seoul, South Korea. The results were presented orally by Professor Cheng Zhou, Director of the Department of Dermatology at Peking University People's Hospital.
CG2001 is a topical fixed-dose combination formulation containing minoxidil and finasteride, being evaluated for the treatment of male androgenetic alopecia.
The trial consisted of the following treatment arms: CG2001 (5% Minoxidil and 0.075% Finasteride) once daily (QD); CG2001 (5% Minoxidil and 0.1% Finasteride) once daily (QD); CG2001 (5% Minoxidil and 0.075% Finasteride) twice daily (BID); and a Control Group.
The study met its primary endpoint: at Week 24, the group treated with CG2001 (5% Minoxidil and 0.075% Finasteride) twice daily demonstrated a statistically significant improvement in the change from baseline in Target Area Hair Count (TAHC) compared to the placebo group. Additionally, favorable safety and tolerability results were observed.
Key topline results include:
- At Week 24, the group treated with CG2001 (5% Minoxidil and 0.075% Finasteride) twice daily achieved an increase of 28.17 hairs/cm² from baseline in TAHC (p=0.006), a key efficacy metric, outperforming the placebo group, which showed an increase of 7.68 hairs/cm².
- In the CG2001 (Minoxidil 5% and Finasteride 0.075%) twice-daily group, a trend of sustained increase in ΔTAHC was observed at Weeks 6, 12, 18, and 24.
- In the CG2001 (Minoxidil 5% and Finasteride 0.075%) twice-daily group a trend toward improvement in subject self-assessments, were also observed.
- CG2001 was generally well-tolerated across all treatment groups, and no sex related adverse event were identified.
- All adverse events were mild to moderate in severity.
"Despite approved treatment options, androgenetic alopecia remains an area of significant unmet medical need. We are encouraged by the Phase II results, which support CG2001's potential as a differentiated treatment option and its continued clinical development," said Baohui Yu, CEO of Dayspring Pharma.
Dayspring Pharma is currently engaging with regulatory authorities to define the next phase of clinical development.
About CG2001
CG2001 is a topical combination of minoxidil and finasteride developed to harness the synergistic potential of two cornerstone therapies for AGA. Both are widely recognized as first-line treatments for male pattern hair loss: minoxidil promotes hair growth, while finasteride inhibits 5α-reductase and reduces dihydrotestosterone levels.
CG2001 is formulated as a specifically designed foam with an optimized dose ratio and delivery system to improve local follicular delivery, enhance efficacy, and minimize systemic exposure associated with oral finasteride.
About Dayspring Pharma
Dayspring Pharma is a pharmaceutical company focused on innovation in dermatology and hair health. The company develops differentiated therapies to address unmet clinical needs. For more information, please visit dayspringpharma.com.
Contact: Dayspring Pharma, chenguang@dayspringpharma.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)
